TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21199097

Group type: EXPERIMENTAL
Intervention: ECA (ethylcyanoacrylate tissue adhesive)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Polypropylene sutures
Number of subjects: 36
Study: 19875425

Group type: EXPERIMENTAL
Intervention: Active strategies to implement the Canadian C‐Spine Rule including education, policy, and real-time reminders on radiology requisitions.
Number of subjects: 11824

Group type: COMPARATOR
Intervention: No specific intervention introduced to alter the behaviour of doctors requesting cervical spine imaging.
Number of subjects: 11824
Study: 17206669

Group type: EXPERIMENTAL
Intervention: Noninflamed ileal mucosa
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Inflamed ileal mucosa
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of noninflamed and inflamed mucosa
Number of subjects: 22
Study: 17277655

Group type: EXPERIMENTAL
Intervention: Gloved fingers
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional laparoscopic instruments
Number of subjects: 15

Group type: COMPARATOR
Intervention: Laparoscopic instrument with sensor
Number of subjects: 15
Study: 12729938

Group type: EXPERIMENTAL
Intervention: 2 mg of sustained‐release melatonin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 9917048

Group type: EXPERIMENTAL
Intervention: 4% cocaine solution for 10 min (160 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4% cocaine solution for 20 min (160 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10% cocaine solution for 20 min (400 mg)
Number of subjects: 12
Study: 7485287

Group type: EXPERIMENTAL
Intervention: Electronic FHR monitoring
Number of subjects: 1419

Group type: COMPARATOR
Intervention: Intermittent auscultation
Number of subjects: 1419
Study: 2186909

Group type: EXPERIMENTAL
Intervention: Once daily netilmicin (n = 98)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Thrice daily netilmicin (n = 99)
Number of subjects: 197
Study: 6986939

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exposure in vivo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clomipramine plus exposure
Number of subjects: 40
Study: 30729945

Group type: COMPARATOR
Intervention: Syringe irrigation (SI) with distilled water (DW)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Syringe irrigation (SI) with 2.5% NaOCl
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Syringe irrigation (SI) with 2.5% Ca(OCl)2
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Laser‐activated irrigation (LAI) with distilled water (DW)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Laser‐activated irrigation (LAI) with 2.5% NaOCl
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Laser‐activated irrigation (LAI) with 2.5% Ca(OCl)2
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Laser‐activated irrigation (LAI) with no solution
Number of subjects: 105
Study: 28467859

Group type: EXPERIMENTAL
Intervention: Bambuterol (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of theophylline and bambuterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bambuterol
Number of subjects: 0
Study: 25169679

Group type: EXPERIMENTAL
Intervention: Information sheet with both implementation intentions and explicit commitment
Number of subjects: 937

Group type: COMPARATOR
Intervention: Control condition (information sheet only)
Number of subjects: 937
Study: 23938173

Group type: EXPERIMENTAL
Intervention: Modafinil (50-200 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 24
Study: 21232120

Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day
Number of subjects: 24
Study: 18497592

Group type: EXPERIMENTAL
Intervention: 12-week psychoeducative nursing intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 16634542

Group type: EXPERIMENTAL
Intervention: Org 9426 0.3 mg x kg(‐1)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Org 9426 0.6 mg x kg(‐1)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Org 9426 0.9 mg x kg(‐1)
Number of subjects: 78
Study: 12738151

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 micro g, followed by two doses of oral misoprostol 100 micro g 4 hours apart (Group 2)
Number of subjects: 1574

Group type: COMPARATOR
Intervention: Intravenous infusion of oxytocin 10 IU plus oral misoprostol 400 micro g, followed by two doses of oral misoprostol 100 micro g 4 hours apart (Group 1)
Number of subjects: 1574

Group type: COMPARATOR
Intervention: Intravenous infusion of oxytocin 10 IU plus intramuscular administration of methylergonovine maleate 0.2 mg (Group 4)
Number of subjects: 1574
Study: 11015543

Group type: EXPERIMENTAL
Intervention: Dust control intervention (cleaning equipment and up to 8 visits by a trained lead hazard control advisor)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 275
Study: 8857441

Group type: EXPERIMENTAL
Intervention: Dopexamine infusion at a dose of 2 microg kg-1 min-1, titrated to achieve normal blood pressure, urine output, and base deficit.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dopexamine infusion
Number of subjects: 17
Study: 1507375

Group type: EXPERIMENTAL
Intervention: Aspirin (two 325‐mg tablets once per day)
Number of subjects: 3711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3711
Study: 6305546

Group type: EXPERIMENTAL
Intervention: Naloxone (6 micrograms/kg/hr)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: D5/W (placebo)
Number of subjects: 6
Study: 31432311

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite gel
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 46
Study: 28259320

Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 MG plus Metronidazole 500 MG 3 times a day for 3 or 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27006286

Group type: EXPERIMENTAL
Intervention: Midazolam (low dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiological saline (control group)
Number of subjects: 0
Study: 24927970

Group type: EXPERIMENTAL
Intervention: Trimetazidine (70 mg/day for 72 hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no trimetazidine)
Number of subjects: 100
Study: 22341495

Group type: EXPERIMENTAL
Intervention: Silver-coated connectors
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-coated connectors
Number of subjects: 25
Study: 19071066

Group type: EXPERIMENTAL
Intervention: Implantable gastric stimulation (stimulation on)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard diet and behavioral therapy (stimulation off)
Number of subjects: 190
Study: 17214729

Group type: EXPERIMENTAL
Intervention: Allylamine-benzoyl peroxide combination therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Proactiv Solution (benzoyl peroxide alone)
Number of subjects: 23
Study: 15565082

Group type: EXPERIMENTAL
Intervention: General low-fat advice with additional targets for food sources of unsaturated fats
Number of subjects: 0

Group type: COMPARATOR
Intervention: General low-fat advice (control group)
Number of subjects: 0
Study: 11408420

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (1 l/h of a 6% carbohydrate beverage)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 98
Study: 9231212

Group type: EXPERIMENTAL
Intervention: artemisinin suppositories followed by mefloquine
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: intramuscular artesunate followed by mefloquine
Number of subjects: 109

Group type: COMPARATOR
Intervention: intravenous quinine followed by pyrimethamine/sulfadoxine
Number of subjects: 109
Study: 8094279

Group type: EXPERIMENTAL
Intervention: Weekly alternating zidovudine (200 mg every 4 hours) and ddC (0.03 mg/kg every 4 hours)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Weekly intermittent zidovudine (200 mg every 4 hours)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Continuous zidovudine therapy
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Alternating regimens (zidovudine and ddC)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Alternating therapy with zidovudine and ddC
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Alternating therapy limbs
Number of subjects: 131

Group type: COMPARATOR
Intervention: Zidovudine alone (intermittently or continuously)
Number of subjects: 131
Study: 3113240

Group type: EXPERIMENTAL
Intervention: 200 micrograms of misoprostol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31419323

Group type: EXPERIMENTAL
Intervention: HAT1
Number of subjects: 14

Group type: COMPARATOR
Intervention: calcipotriol 0.005%
Number of subjects: 14
Study: 29906642

Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 27438170

Group type: EXPERIMENTAL
Intervention: Nonintubated ETS using a needle endoscope (group A, n=108)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Traditional transaxillary single-port ETS using a 5-mm thoracoscope (group B, n=113)
Number of subjects: 221
Study: 25011667

Group type: EXPERIMENTAL
Intervention: Repetitive motor task under vibratory feedback and 3D motor characterization
Number of subjects: 44

Group type: COMPARATOR
Intervention: 3D motor characterization only
Number of subjects: 44
Study: 23229457

Group type: EXPERIMENTAL
Intervention: mini-midvastus approach
Number of subjects: 89

Group type: COMPARATOR
Intervention: mini-medial parapatellar approach
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 89
Study: 20448107

Group type: EXPERIMENTAL
Intervention: Melphalan-prednisone and thalidomide (MPT)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Melphalan-prednisone and placebo (MP)
Number of subjects: 363
Study: 18566593

Group type: EXPERIMENTAL
Intervention: valsartan
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: ramipril
Number of subjects: 369

Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 369
Study: 16336334

Group type: EXPERIMENTAL
Intervention: Transurethral vapour resection of the prostate (TUVRP)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HOLEP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 150
Study: 12829910

Group type: EXPERIMENTAL
Intervention: TAC + MMF
Number of subjects: 223

Group type: COMPARATOR
Intervention: CsA + MMF
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: TAC + AZA
Number of subjects: 223
Study: 10743480

Group type: EXPERIMENTAL
Intervention: High-protein soya milk
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cows' milk
Number of subjects: 21
Study: 7496696

Group type: EXPERIMENTAL
Intervention: Iodixanol 270 mgI ml‐1
Number of subjects: 140

Group type: COMPARATOR
Intervention: Iopamidol 300 mgI ml‐1
Number of subjects: 140
Study: 1675534

Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide
Number of subjects: 106

Group type: COMPARATOR
Intervention: Topical meclocycline sulfosalicylate
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Combined treatment (topical meclocycline sulfosalicylate and benzoyl peroxide)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 106
Study: 6799032

Group type: EXPERIMENTAL
Intervention: Lithium therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 38
Study: 31412895

Group type: EXPERIMENTAL
Intervention: Standard TB therapy (for HIV-positive patients)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Standard TB therapy (for HIV-negative patients)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Standard TB therapy (for both groups)
Number of subjects: 262
Study: 29135593

Group type: EXPERIMENTAL
Intervention: Dynamic needle tip positioning technique (n = 132)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Palpation technique (n = 128)
Number of subjects: 260
Study: 27855166

Group type: EXPERIMENTAL
Intervention: ATG-F
Number of subjects: 35

Group type: COMPARATOR
Intervention: Thymoglobulin
Number of subjects: 35
Study: 25001153

Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 534

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 534
Study: 22463733

Group type: EXPERIMENTAL
Intervention: Directed home medicines review service
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual post-discharge care
Number of subjects: 100
Study: 20049950

Group type: EXPERIMENTAL
Intervention: pH-dependent release formulation 3.6 g/day
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: pH-dependent release formulation 2.4 g/day
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Time-dependent release formulation 2.25 g/day
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: pH-dependent release formulations (2.4 g and 3.6 g)
Number of subjects: 229
Study: 18411384

Group type: EXPERIMENTAL
Intervention: Basal insulin therapy using glargine self-titrated according to a patient algorithm
Number of subjects: 405

Group type: COMPARATOR
Intervention: Conventional therapy with physician-adjusted doses of oral agents
Number of subjects: 405
Study: 16080936

Group type: EXPERIMENTAL
Intervention: Seprafilm
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control
Number of subjects: 122
Study: 11834996

Group type: EXPERIMENTAL
Intervention: Immediate spinal cord decompression (protocol group)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Reference group (non-protocol patients)
Number of subjects: 91
Study: 10187866

Group type: EXPERIMENTAL
Intervention: Stroke Units (SUs)
Number of subjects: 14308

Group type: COMPARATOR
Intervention: General Wards (GWs)
Number of subjects: 14308
Study: 7497137

Group type: EXPERIMENTAL
Intervention: Regular mammographic screening every 33 months (every 24 months for those aged 40-49)
Number of subjects: 21925

Group type: COMPARATOR
Intervention: Unscreend control group
Number of subjects: 21925
Study: 1690342

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 0
Study: 397711

Group type: EXPERIMENTAL
Intervention: Nefopam 15 mg (maximum 90 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oxycodone 4 mg (maximum 24 mg)
Number of subjects: 16
Study: 6287928

Group type: EXPERIMENTAL
Intervention: Intranasal enviroxime (one spray per nostril, five times per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intranasal enviroxime
Number of subjects: 40
Study: 31237727

Group type: EXPERIMENTAL
Intervention: 75 mg risankizumab
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 150 mg risankizumab
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 29562156

Group type: EXPERIMENTAL
Intervention: Venetoclax plus rituximab
Number of subjects: 389

Group type: COMPARATOR
Intervention: Bendamustine plus rituximab
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Venetoclax plus rituximab (in patients with chromosome 17p deletion)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Bendamustine plus rituximab (in patients with chromosome 17p deletion)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Venetoclax plus rituximab (in patients without chromosome 17p deletion)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Bendamustine plus rituximab (in patients without chromosome 17p deletion)
Number of subjects: 389
Study: 26171754

Group type: EXPERIMENTAL
Intervention: Video consultation during monthly home visits
Number of subjects: 188

Group type: COMPARATOR
Intervention: Regular monthly home visits (no video consultation)
Number of subjects: 188
Study: 24881178

Group type: EXPERIMENTAL
Intervention: Self-testing of two catheters by continence nurses.
Number of subjects: 16
Study: 22304676

Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA) bibliotherapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combined treatment groups (post-treatment and 1-month follow-up)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combined treatment groups (1-month follow-up)
Number of subjects: 26
Study: 20467191

Group type: EXPERIMENTAL
Intervention: Exercise intervention (aerobic and resistance exercise programs for 3 months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group without exercise training
Number of subjects: 38
Study: 17591303

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IV cannulation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Traditional method of IV cannulation
Number of subjects: 35
Study: 16228157

Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 200

Group type: COMPARATOR
Intervention: Gravity drainage
Number of subjects: 200
Study: 12365197

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 120 mg
Number of subjects: 12
Study: 10421239

Group type: EXPERIMENTAL
Intervention: Pramlintide (30 microg four times daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7472685

Group type: EXPERIMENTAL
Intervention: Physicians with positive attitudes toward psychosocial aspects of care
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Patients of physicians with positive attitudes
Number of subjects: 473
Study: 2264198

Group type: COMPARATOR
Intervention: No additional therapeutic measures (Group 1)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Immunotherapy with the BCG vaccine (Group 2)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Levamisole for immunotherapy (Group 3)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Combined method: BCG vaccine, placental suspension, and cyclophosphamide (Group 4)
Number of subjects: 89
Study: 7406204

Group type: EXPERIMENTAL
Intervention: HAL (Halothane)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NAL (Nitrous Oxide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EHA (Enflurane)
Number of subjects: 0
Study: 29952829

Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol (PEG)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 28869573

Group type: EXPERIMENTAL
Intervention: LEU (L-leucine)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Whey Protein Concentrate (WPC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Whey Protein Hydrolysate (WPH)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Soy Protein Concentrate (SPC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Maltodextrin Placebo (PLA)
Number of subjects: 75
Study: 26187233

Group type: EXPERIMENTAL
Intervention: Caloric Restriction (CR) - 25% reduction in caloric intake
Number of subjects: 218

Group type: COMPARATOR
Intervention: Ad libitum (AL) diet
Number of subjects: 218
Study: 23573255

Group type: EXPERIMENTAL
Intervention: Cyberball-induced exclusion (SE)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cyberball-induced inclusion (SI)
Number of subjects: 43
Study: 21365629

Group type: EXPERIMENTAL
Intervention: Combination of Lonafarnib (LNF) and Docetaxel (DTX)
Number of subjects: 38
Study: 17522596

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (5-20 cm2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivastigmine capsules (1.5-6 mg Q12H, i.e., 3-12 mg/day)
Number of subjects: 0
Study: 16440148

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) administered intravenously during the operation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine CABG protocol (Control group)
Number of subjects: 20
Study: 12691318

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy with cisplatin, vincristine, bleomycin (NACT arm)
Number of subjects: 192

Group type: COMPARATOR
Intervention: conventional surgery or radiotherapy alone (CO arm)
Number of subjects: 192
Study: 10891820

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (1 mg/m²/d) for 24 months
Number of subjects: 35
Study: 8979288

Group type: COMPARATOR
Intervention: Fluticasone propionate, 200 micrograms
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate, 400 micrograms
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate, 800 micrograms
Number of subjects: 17
Study: 8102222

Group type: EXPERIMENTAL
Intervention: Systemic vecuronium
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isolated forearm vecuronium
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonisolated arm vecuronium
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Repeated systemic vecuronium
Number of subjects: 10
Study: 3519883

Group type: EXPERIMENTAL
Intervention: L-phenylalanine mustard (L-PAM)
Number of subjects: 0
Study: 31751466

Group type: EXPERIMENTAL
Intervention: 200 mg L-DOPA
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 29664406

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 28381428

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 26088460

Group type: EXPERIMENTAL
Intervention: Pre-RT temozolomide followed by concurrent temozolomide and radiotherapy (RT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pre-RT temozolomide followed by concurrent temozolomide and RT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pre-RT temozolomide followed by concurrent temozolomide and RT in codeleted patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pre-RT temozolomide followed by concurrent temozolomide and RT in non-codeleted patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison with codeleted procarbazine/CCNU/vincristine (PCV) and RT cohort in RTOG 9402
Number of subjects: 40
Study: 23017467

Group type: EXPERIMENTAL
Intervention: Food addiction symptomology
Number of subjects: 57